Aparna Vijayasekaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aparna Vijayasekaran has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Amy C. Degnim
Department of Surgery, Mayo Clinic, Rochester, USA
21 shared publications - Brittany L. Siontis
Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
21 shared publications - Christian L. Baum
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA
21 shared publications - Courtney Day
Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
21 shared publications - Ivy A. Petersen
Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
21 shared publications - James W. Jakub
Department of Surgery, Mayo Clinic, Jacksonville, USA
21 shared publications
Latest Publications
- 9 October 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 124, 5-12
Impact of a neck exoskeleton device on plastic surgery resident ergonomics
- 9 October 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 124, 5-12
Impact of a neck exoskeleton device on plastic surgery resident ergonomics
- 22 July 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 121, 81-92
Evidence-based insights into medial pedicle reduction mammaplasty: A systematic review and meta-analysis
- 22 July 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 121, 81-92
Evidence-based insights into medial pedicle reduction mammaplasty: A systematic review and meta-analysis
- Open Access
- 19 June 2026
- Published by Elsevier in JPRAS Open
- Vol. 51, 169-179
Liposomal bupivacaine after reduction mammaplasty: is it worth the shot? A single-blind, breast-split randomized clinical trial
- 19 June 2026
- Published by Elsevier in JPRAS Open
- Vol. 51, 169-179
Open AccessLiposomal bupivacaine after reduction mammaplasty: is it worth the shot? A single-blind, breast-split randomized clinical trial
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 1. Clinical response in one representative patient treated with trimodality therapy who experienced a pathologic complete response to preoperative chemoradiation; a) baseline photograph at time of diagnosis/ Pre-treatment, b) photograph after induction chemotherapy, c) photograph after completion of chemoradiation, prior to surgery.
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 1. Clinical response in one representative patient treated with trimodality therapy who experienced a pathologic complete response to preoperative chemoradiation; a) baseline photograph at time of diagnosis/ Pre-treatment, b) photograph after induction chemotherapy, c) photograph after completion of chemoradiation, prior to surgery.
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 2. Kaplan Meier survival curve of local recurrence free survival (LRFS).
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 2. Kaplan Meier survival curve of local recurrence free survival (LRFS).
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 3. Kaplan Meier survival curve of distant recurrence free survival (DRFS).
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 3. Kaplan Meier survival curve of distant recurrence free survival (DRFS).
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Purpose:To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment.Experimental Design:With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins.Results:A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P < 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3–44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing.Conclusions:Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Purpose:To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment.Experimental Design:With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins.Results:A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P < 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3–44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing.Conclusions:Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 3. Kaplan Meier survival curve of distant recurrence free survival (DRFS).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 3. Kaplan Meier survival curve of distant recurrence free survival (DRFS).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 1. Clinical response in one representative patient treated with trimodality therapy who experienced a pathologic complete response to preoperative chemoradiation; a) baseline photograph at time of diagnosis/ Pre-treatment, b) photograph after induction chemotherapy, c) photograph after completion of chemoradiation, prior to surgery.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 1. Clinical response in one representative patient treated with trimodality therapy who experienced a pathologic complete response to preoperative chemoradiation; a) baseline photograph at time of diagnosis/ Pre-treatment, b) photograph after induction chemotherapy, c) photograph after completion of chemoradiation, prior to surgery.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 2. Kaplan Meier survival curve of local recurrence free survival (LRFS).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 2. Kaplan Meier survival curve of local recurrence free survival (LRFS).